recombinant hepatitis B vaccine
Commercial- Indications
- Hepatitis B
Company intelligence / Profile preview
AIM Honesty
China
- Ownership
- Private
- Development stage
- Commercial
01
Overview
AIM Honesty is a wholly owned, active subsidiary of AIM Vaccine, focused on the R&D and manufacture of genetically engineered vaccines, with several commercialized vaccines and ongoing R&D in additional vaccine modalities. It is one of the main GMP-certified manufacturing arms of AIM Vaccine, contributing to both marketed and pipeline products[3][4][9].
- Therapeutic areas
- Infectious Diseases
- Modalities
- VaccinemRNA-based drugsRecombinant protein
- Industry
- Pharma
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on AIM Honesty.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AIM Honesty.